DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Most safety profiles were grade 1 and 2. Treatment with 80 mg once daily osimertinib achieved a median OS of 15.0 months and an objective response rate of 51.6%, alongside a disease control rate of 81 ...

AstraZeneca's Farxiga reduced the risk of ... The study showed that treatment with Farxiga (dapagliflozin) led to an 18% reduction in cardiovascular death or worsening heart failure in patients ...

AstraZeneca's lengthy and turbulent development ... The FDA approval covers a single 300 mg dose of Imjudo given alongside 1,500 mg Imfinzi, followed by Imfinzi every four weeks – known as ...

Technologycategory· June 4, 2025 Brookfield plans $10 billion AI data centre in Sweden ... 2025 Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk Treating ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...